Art. -Nr.: HY-113914

9-ING-41

(Synonyms: Elraglusib)

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC₅₀ of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.13%
CAS. Nr.: 1034895-42-5
Formel: C₂₂H₁₃FN₂O₅
Molecular Weight:404.35

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

9-ING-41 Chemical Structure

CAS. Nr.: 1034895-42-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

GSK-3β

0.71 μM (IC₅₀)

Alle GSK-3 Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	IC₅₀	1 μM Compound: 26	Growth inhibition of human BxPC3 cells after 72 hrs by MTS assay Growth inhibition of human BxPC3 cells after 72 hrs by MTS assay	[PMID: 19338355]
HuP-T3	IC₅₀	0.6 μM Compound: 26	Growth inhibition of human HUPT3 cells after 72 hrs by MTS assay Growth inhibition of human HUPT3 cells after 72 hrs by MTS assay	[PMID: 19338355]
MIA PaCa-2	IC₅₀	5 μM Compound: 26	Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 19338355]

In Vitro

9-ING-41 (compound 26; 5 μM; for 6, 12, 24, 36 h) results in a pronounced decrease in NFκB-mediated expression of XIAP, the most potent antiapoptotic protein, leading to subsequent apoptosis in BXPC3 pancreatic cancer cells^[1].
?9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis^[2].
? 9-ING-41 (1, 2 μM; 24 hours) is a potent cell cycle-blocking agent for lymphoma cells^[2].
? 9-ING-41 (10?μM; for 72?hours) increases the expression of LC3, an autophagy marker^[3].
? 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM^[2].
? 9-ING-41 (10?μM; for 72?hours) causes cell cycle blockage at G2/M after 24?hours. 9-ING-41 treatment induces apoptotic cell death in bladder cancer cells^[3].
? 9-ING-41 (25?μM; for 96?hours) significantly decreases expression of Cdk1 and Cyclin B1 proteins and leads to a decreased expression of antiapoptotic molecules, Bcl-2 and XIAP^[3].
? 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

TCL and MCL lines
Concentration:

2, 4 μM
Incubation Time:

48 hours
Result:

Induced apoptosis.

Cell Cycle Analysis^[2]

Cell Line:

Lymphoma cells (Jeko, Mino, and OCI-Ly cell lines)
Concentration:

1, 2 μM
Incubation Time:

24 hours
Result:

Led to cell cycle arrest in G2/M.

Cell Autophagy Assay^[3]

Cell Line:

T24 cancer cells
Concentration:

25 μM
Incubation Time:

24 hours
Result:

Showed extensive vacuolation and formation of autophagosome like structures in the cytoplasm.
Showed an increased expression of LC3, an autophagy marker.

Western Blot Analysis^[4]

Cell Line:

SK-N-DZ and SK-N-BE neuroblastoma cells
Concentration:

0.1, 1 µM
Incubation Time:

48 hours
Result:

Inhibited GSK-3 leading to a decreased expression of the NF-κB target XIAP.

In Vivo

9-ING-41 (40 mg/kg/every other day; for 17 days) has single-agent antitumor activity in a mouse model of MCL^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NSG (NOD.Cg-Prkdc^scidIl2rg^tm1Wjl/SzJ) mice^[2]
Dosage:

40 mg/kg
Administration:

Every other day; for 17 days
Result:

Had single-agent antitumor activity in a mouse model of MCL.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1034895-42-5
Appearance Solid
Molecular Weight 404.35
Formel C₂₂H₁₃FN₂O₅
Color Pink to red
SMILES

O=C(C(C1=COC2=CC=C(F)C=C12)=C3C4=CN(C)C5=C4C=C6C(OCO6)=C5)NC3=O
Synonyms

Elraglusib
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All Cell Proliferation/Viability AssayCell Imaging/StainingHistological Imaging/StainingIHC

Sort by:

Journal Impact Factor

Nature

Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. [Abstract]

2025 Jun;642(8067):508-518. PMID: 40240608

9-ING-41 purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jun;642(8067):508-518. [Abstract]

Analysis of cell viability in THP-1 cells treated with the indicated inhibitors for 5 days by the Cell-Titer-Glo assay.

9-ING-41 purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jun;642(8067):508-518. [Abstract]

Wright-Giemsa-stained cytospins for a DNMT3A-mutant primary AML sample treated with DMSO, IMG-7289 (50 nM), 9-ING-41 (100 nM) and combination of both inhibitors.
Adv Sci (Weinh)

Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy. [Abstract]

2024 Feb;11(5):e2303088. PMID: 38018486
Clin Cancer Res

2025 Dec 9.
Front Immunol

Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer. [Abstract]

2024 May 15:15:1360436. PMID: 38812516

9-ING-41 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2024 May 15:15:1360436. [Abstract]

Bladder cancer cells (MB49) and normal cells (NIH3T3) were treated with 0–10 μM of 9-ING-41 for 48 h The cell viability was determined by MTT assay.

9-ING-41 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2024 May 15:15:1360436. [Abstract]

MB49 tumor tissues of mice treated with PBS, 9-ING-41 (10 mg/kg), HY-oAd, and HY-oAd+9-ING-41 were stained with Masson’s trichrome to assess collagen accumulation in the tumor tissues.

9-ING-41 purchased from MedChemExpress. Usage Cited in: Front Immunol. 2024 May 15:15:1360436. [Abstract]

Immunohistochemical staining of CD4+ and CD8+ T cells from subcutaneous MB49 tumor tissue sections obtained after treatment with PBS, 9-ING-41 (10 mg/kg), HY-oAd, and HY-oAd+9-ING-41.
Cancer Biol Ther

Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL). [Abstract]

2025 Dec 31;26(1):2581831. PMID: 41220107
bioRxiv

2025 Oct 6.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (123.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4731 mL

12.3655 mL

24.7310 mL

5 mM

0.4946 mL

2.4731 mL

4.9462 mL

10 mM

0.2473 mL

1.2366 mL

2.4731 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Irina N Gaisina, et al. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52(7):1853-63. [Content Brief]

[2]. Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373. [Content Brief]

[3]. Hiroo Kuroki, et al. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977. [Content Brief]

[4]. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4731 mL	12.3655 mL	24.7310 mL	61.8276 mL
	5 mM	0.4946 mL	2.4731 mL	4.9462 mL	12.3655 mL
	10 mM	0.2473 mL	1.2366 mL	2.4731 mL	6.1828 mL
	15 mM	0.1649 mL	0.8244 mL	1.6487 mL	4.1218 mL
	20 mM	0.1237 mL	0.6183 mL	1.2366 mL	3.0914 mL
	25 mM	0.0989 mL	0.4946 mL	0.9892 mL	2.4731 mL
	30 mM	0.0824 mL	0.4122 mL	0.8244 mL	2.0609 mL
	40 mM	0.0618 mL	0.3091 mL	0.6183 mL	1.5457 mL
	50 mM	0.0495 mL	0.2473 mL	0.4946 mL	1.2366 mL
	60 mM	0.0412 mL	0.2061 mL	0.4122 mL	1.0305 mL
	80 mM	0.0309 mL	0.1546 mL	0.3091 mL	0.7728 mL
	100 mM	0.0247 mL	0.1237 mL	0.2473 mL	0.6183 mL

Keywords

9-ING-41

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

9-ING-41

Apoptosis Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Chemotherapy Drug Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) 9-ING-41

Alle GSK-3 Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

9-ING-41 Related Classifications

HY-113914 Related Classifications